Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has issued an update.
Lepu Biopharma Co., Ltd. announced the resignation of Mr. Yang Hongbing from his position as a non-executive director due to personal and professional commitments. The board expressed gratitude for his contributions and proposed the appointment of Ms. Qin Yiran as his successor, pending shareholder approval at the upcoming annual general meeting. Ms. Qin, currently an investment director at Hainan Shiyu Private Equity Management Co., Ltd., brings a strong background in biology and investment management to the role, potentially enhancing the company’s strategic direction.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on developing and providing innovative medical solutions and treatments.
Average Trading Volume: 18,899,809
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.07B
For an in-depth examination of 2157 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue